Applied DNA Sciences First Quarter 2024 Earnings: Beats Expectations
Applied DNA Sciences (NASDAQ:APDN) First Quarter 2024 Results
Key Financial Results
Revenue: US$891.2k (down 83% from 1Q 2023).
Net loss: US$1.03m (loss narrowed by 73% from 1Q 2023).
US$0.075 loss per share (improved from US$0.30 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Applied DNA Sciences Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 71%.
Looking ahead, revenue is expected to decline by 4.5% p.a. on average during the next 2 years, while revenues in the Life Sciences industry in the US are expected to grow by 6.1%.
Performance of the American Life Sciences industry.
The company's shares are up 6.2% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Applied DNA Sciences (1 makes us a bit uncomfortable) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
